UB Paderborn / Katalog / Suche / in CDI

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2016-05, Vol.34 (15), p.1723-1731

2016

Volltextzugriff (PDF)

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2013-01, Vol.381 (9863), p.303-312

2013

Volltextzugriff (PDF)

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

Journal of cancer research and clinical oncology, 2014-09, Vol.140 (9), p.1615-1624

2014

Volltextzugriff (PDF)

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2311-2319

2008

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

NeoFLOT II: Multicenter phase II study with short time neoadjuvant chemotherapy (stNACT) with 5-FU, FA, oxaliplatin, and docetaxel in rectable adenocarcinoma of the gastresophageal junction and gastric adenocarcinoma (T3, T4, and/or LN+) with high R0 resection rate over 91.5

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4061-4061

2015

Volltextzugriff (PDF)

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4133-TPS4133

2017

Volltextzugriff (PDF)

A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3049-3049

2015

Volltextzugriff (PDF)

Aflibercept/Folfiri vs Placebo/Folfiri in Metastatic Colorectal Cancer: A Post-Hoc Analysis of Median Overall Survival in Velour from the Retrospectively Assessed Time of Starting First-Line Treatment

Annals of oncology, 2014-06, Vol.25, p.ii104-ii104

2014

Volltextzugriff (PDF)

Panitumumab (pmab) in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC): Final analysis from a community-based, observational study (VECTOR) in Germany

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.550-550

2013

Volltextzugriff (PDF)

Observational study of adjuvant therapy with capecitabine in colon cancer

Current medical research and opinion, 2015-04, Vol.31 (4), p.731-741

2015

Volltextzugriff (PDF)

Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.680-680

2015

Volltextzugriff (PDF)

SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.637-637

2016

Volltextzugriff (PDF)

Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3643-3643

2013

Volltextzugriff (PDF)

Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e14562-e14562

2014

Volltextzugriff (PDF)

Updated Results of the Randomized Phase 2 Impact Trial: Maintenance with TLR-9 Agonist Mgn1703 Vs Placebo in Patients with Metastatic Colorectal Carcinoma (MCRC)

Annals of oncology, 2013-06, Vol.24, p.iv16-iv16

2013

Volltextzugriff (PDF)

Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e14560-e14560

2014

Volltextzugriff (PDF)

Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703

Cancer immunology research, 2015-10, Vol.3 (10_Supplement), p.B61-B61

2015

Volltextzugriff (PDF)

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 \+/-\ bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) \+/-\ bev in patients (pts) with metastatic colorectal cancer (mCRC)

Asia-Pacific journal of clinical oncology, 2015, Vol.11 (Special issue: ASCO Annual Meeting), p.68-69

2015

Volltextzugriff (PDF)

Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer

Clinical colorectal cancer, 2005-11, Vol.5 (4), p.257-262

2005

Volltextzugriff (PDF)

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Journal of thrombosis and haemostasis, 2019-10, Vol.17 (10), p.1694-1706

2019

Volltextzugriff (PDF)

Alterations in Structure and Cellular Localization of Molecular Forms of DP IV/CD26 during T Cell Activation

Cellular immunology, 1996-05, Vol.170 (1), p.63-70

1996

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

NeoFLOT II: Multicenter phase II study with short time neoadjuvant chemotherapy (stNACT) with 5-FU, FA, oxaliplatin, and docetaxel in rectable adenocarcinoma of the gastresophageal junction and gastric adenocarcinoma (T3, T4, and/or LN+) with high R0 resection rate over 91.5

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO

A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703

Aflibercept/Folfiri vs Placebo/Folfiri in Metastatic Colorectal Cancer: A Post-Hoc Analysis of Median Overall Survival in Velour from the Retrospectively Assessed Time of Starting First-Line Treatment

Panitumumab (pmab) in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC): Final analysis from a community-based, observational study (VECTOR) in Germany

Observational study of adjuvant therapy with capecitabine in colon cancer

Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival

SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC)

Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT)

Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies)

Updated Results of the Randomized Phase 2 Impact Trial: Maintenance with TLR-9 Agonist Mgn1703 Vs Placebo in Patients with Metastatic Colorectal Carcinoma (MCRC)

Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program

Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 \+/-\ bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) \+/-\ bev in patients (pts) with metastatic colorectal cancer (mCRC)

Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Alterations in Structure and Cellular Localization of Molecular Forms of DP IV/CD26 during T Cell Activation

Suchergebnisse filtern